Surgicel
Phase 3Cell therapy
Surgicel is one of 15 small molecule programs targeting Knee Osteoarthritis. It is currently in Phase 3.
2
Indications
4
Total Trials
1
Active Trials
14
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
15 competitors in Knee Osteoarthritis
#DrugCompanyPhaseTrials
1Cymbalta
Jazz PharmaceuticalsApproved
Surgicel
PPeking University Third Hospital
Phase 3
Inulin and Sodium Chloride
BBlue Earth Diagnostics
Phase 2
PTP-01
DDoron Therapeutics Inc.
Phase 3
Medrol
PfizerPreclinical
Allocetra
EEnlivex Therapeutics Ltd.
Phase 2
Decadron
AAspen Global Incorporated
Preclinical
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Preclinical
Solu-Medrol
MMassachusetts Eye and Ear Infirmary
Preclinical
Paracetamol
GSKPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Heavy Menstrual Bleeding1 trial
Surgicel® & Endometrial Ablation in the Management of Perimenpausal Heavy Menstrual Bleeding
Unknown status·—·Phase 2·NCT03176992·240 enrolled
Endometrioma1 trial
Surgicel Reduces Ovarian Endometriomas Recurrence
Completed·—·Phase 2·NCT02947724·200 enrolled
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Surgicel. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Cell therapy[2]
- Highest Phase
- Phase 3[1]
- Company
- PPeking University Third Hospital